Saniona AB: Saniona approved for listing on Nasdaq Stockholm's main market

Print
| Source: Saniona AB
multilang-release

PRESS RELEASE

31 May 2017

On 30 May 2017, Nasdaq Stockholm's Listing Committee has on customary terms approved that trading in the shares of Saniona AB (publ) ("Saniona") is moved to the main market and consequently delisted from Nasdaq First North Premier. The first day of trading on the main market is planned to be 15 June 2017 and the last day of trading on Nasdaq First North Premier will therefore be 14 June 2017. The share will be traded within the Small Cap segment under the ticker "SANION". Saniona will keep the same ISIN-code as before, i.e. SE0005794617. No new shares are issued in connection with the listing on Nasdaq Stockholm and shareholders in Saniona do not need to take any action in connection hereto.

Saniona was listed on AktieTorget on 22 April 2014 and on Nasdaq Firth North Premier on 19 May 2016.

"During the course of approximately one year, we have moved Saniona from a biotech company with programs in discovery to a biotech company with several programs in late stage clinical development. In parallel hereto, we have entered into several new collaborations with pharmaceutical companies. Saniona has today a broad and mature pipeline of internal and partnered pharmaceutical programs in indications with significant medical need where we believe we have good opportunities to create value for our shareholders," says Jørgen Drejer, CEO of Saniona.

"A listing on Nasdaq Stockholm will create better conditions to broaden the shareholder base and give the company access to the Swedish and the international capital markets. The listing on Nasdaq Stockholm will also increase the knowledge of Saniona and its business among current and potential partners and suppliers."

A prospectus related to the listing on Nasdaq Stockholm is planned to be made public on or around 12 June 2017. The prospectus will be available on Saniona's website, www.saniona.com.

Pareto Securities has acted as financial adviser and Setterwalls Advokatbyrå AB as legal adviser in connection with the listing.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com

The information in this interim report is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and Sweden's Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 12:30 CET on 31 May 2017.

About Saniona

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Luc Therapeutics Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 5,000 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/6e530cfc-f0cf-4a1e-a543-e7ae5d702d45